Research Peptide
DSIP (Delta Sleep-Inducing Peptide)
Alternative Name: Delta Sleep, Hypnos Sequence Length: 9 amino acid sequence
Molecular Structure
Chemical Properties
Molecular Mass: 848.81 g/mol
Molecular Formula: C35H48N10O15
CAS Number: 62568-57-4
Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Half-Life: approximately 7-15 minutes
Typical Purity: >98%
Administration Routes: subcutaneous, intramuscular, intranasal
Overview
Delta Sleep-Inducing Peptide (DSIP) is a synthetic form of a naturally occurring nonapeptide composed of nine amino acids. It was first isolated in 1977 from the cerebral venous blood of rabbits following electrical stimulation of the intralaminar thalamus, a brain region associated with sleep regulation. Early animal studies observed increased delta-wave activity after administration of purified peptide fractions, leading to the name “Delta Sleep-Inducing Peptide.”
Subsequent research has shown that DSIP exhibits a broader and more complex pattern of biological activity than originally proposed. Researchers have investigated its interactions with central nervous system signaling, neuroendocrine regulation, and stress-responsive molecular pathways. Published studies have examined DSIP in experimental models involving sleep architecture, circadian rhythm regulation, hypothalamic-pituitary-adrenal (HPA) axis signaling, cortisol regulation, endogenous opioid pathways, and alcohol- and opioid-withdrawal models. Additional investigations have explored its influence on pain-related signaling, autonomic nervous system activity, and neurotransmitter systems including gamma-aminobutyric acid (GABA) and adrenergic signaling.
Despite more than four decades of scientific investigation, DSIP’s primary molecular target has not been conclusively identified, and its biological mechanism remains incompletely understood. Much of the available evidence has been generated in preclinical research and experimental models, while published human studies remain limited. As a result, additional research is needed to further characterize its receptor interactions, molecular signaling pathways, and physiological functions.
Research Use Only: DSIP is intended exclusively for laboratory research and analytical purposes. It is an investigational research compound and has not been approved by the U.S. Food and Drug Administration (FDA).
Mechanism of Action
The molecular mechanism of DSIP has not been fully characterized. Unlike many peptide signaling molecules, no specific receptor has been conclusively identified for DSIP. Current evidence suggests that its biological activity may result from modulation of several interconnected signaling systems rather than activation of a single receptor. Additional research is needed to determine its primary molecular target.
Published studies have examined DSIP’s influence on gamma-aminobutyric acid (GABA) signaling, where it has been proposed to modulate GABAergic neurotransmission in experimental models. Researchers have also investigated interactions with adrenergic pathways, including possible effects on noradrenergic signaling and activity within the locus coeruleus. These observations suggest that DSIP may participate in regulation of neuronal communication, although the underlying mechanisms remain unproven.
Researchers have further examined DSIP’s interactions with endogenous opioid signaling. Experimental studies have proposed that the peptide may influence enkephalin and endorphin pathways, while additional investigations have explored its effects on hypothalamic-pituitary signaling. Published research has reported changes in the release of several pituitary hormones under specific experimental conditions, suggesting that DSIP may participate in neuroendocrine regulation through central nervous system pathways. These findings have not been consistent across all studies.
Additional experimental models have investigated whether DSIP interacts directly with neuronal membranes. Some studies have proposed that the peptide may influence membrane stability and calcium channel activity independently of classical receptor-mediated signaling. Because a primary receptor has not been identified, researchers have also suggested that DSIP may function as a regulatory peptide that indirectly influences multiple cellular pathways.
Overall, published research indicates that DSIP exhibits complex biological activity involving several neurotransmitter systems, neuroendocrine pathways, and intracellular signaling networks. However, the absence of a clearly identified receptor and the variability of experimental findings indicate that its mechanism of action remains incompletely understood. Additional research is needed to clarify its molecular targets, receptor interactions, and role in normal cellular signaling.
Research Use Only: DSIP is intended exclusively for laboratory research and analytical purposes. It is an investigational research compound and has not been approved by the U.S. Food and Drug Administration (FDA).
Research Papers
The influence of synthetic DSIP (delta–sleep–inducing–peptide) on disturbed human sleep.
Experientia. 1981;37(9):913-7. doi: 10.1007/BF01971753.PMID: 7028502
Effects of delta–sleep–inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.
Delta sleep–inducing peptide (DSIP): a still unresolved riddle.
Related Compounds and Research Pathways
Research Context: Compounds listed below share areas of scientific investigation or molecular signaling. Inclusion does not indicate compatibility, combined use, or a recommendation to combine research compounds. Relationships describe similarities or differences reported in published research.
Overlapping Research Pathways:
- Melatonin: DSIP and melatonin have both been studied in research involving sleep-related signaling and biological sleep cycles, but they are linked to different pathways. DSIP research has examined sleep patterns and nervous system signaling, while melatonin research has focused on circadian rhythms and melatonin receptor signaling. These compounds therefore share related areas of sleep research, although a direct molecular relationship between them has not been fully established.
Related Research Areas:
- Selank: DSIP and Selank have both been studied in research involving nervous system signaling and stress-related pathways. DSIP research has focused mainly on sleep-related signaling and sleep patterns, while Selank has been investigated for its effects on GABA and other neurotransmitter systems. These compounds share related areas of nervous system research, although their exact biological mechanisms are different.
- Epithalon: DSIP and Epithalon have both been studied in research involving sleep cycles and the body’s biological clock. DSIP research has focused on sleep patterns and nervous system signaling, while Epithalon has been investigated in relation to circadian rhythm and cellular timing pathways. These compounds share related areas of biological rhythm research, although their molecular mechanisms are different.
Opposing Pathways:
- Benzodiazepines: DSIP and benzodiazepines have both been studied in research involving central nervous system activity and sleep-related signaling, but they act through different mechanisms. Benzodiazepines primarily affect GABA-A receptor signaling, while DSIP has been investigated across several neurotransmitter and sleep-related pathways. These mechanisms may influence some of the same nervous system processes, although their molecular relationship is not fully understood.
Frequently Asked Questions
- What is DSIP? Delta Sleep-Inducing Peptide (DSIP) is a synthetic version of a naturally occurring nonapeptide composed of nine amino acids. Since its discovery in 1977, DSIP has been investigated for its potential role in central nervous system signaling, neuroendocrine regulation, and circadian biology. Although extensively studied, its primary molecular target has not been conclusively identified.
- What does DSIP stand for? DSIP stands for Delta Sleep-Inducing Peptide. The name originated from early animal experiments in which increased delta-wave EEG activity was observed following administration of purified peptide fractions. Later research has suggested that DSIP exhibits a broader range of biological activity than its name implies.
- How does DSIP work? The mechanism of action of DSIP remains incompletely understood. Researchers have investigated its interactions with GABAergic neurotransmission, adrenergic signaling, endogenous opioid pathways, hypothalamic-pituitary-adrenal (HPA) axis regulation, and neuronal membrane signaling. No definitive receptor has been identified, and additional research is needed to fully characterize its molecular targets.
- What biological processes has DSIP been studied for? Published studies have investigated DSIP in experimental models involving sleep architecture, circadian rhythm regulation, stress-responsive molecular signaling, HPA axis activity, endogenous opioid signaling, neurotransmitter regulation, and neuroendocrine communication. Additional research has examined its biological activity in alcohol- and opioid-withdrawal models and pain-related molecular pathways.
- Is DSIP a naturally occurring peptide? Yes. DSIP-like peptides have been detected in human plasma, cerebrospinal fluid, and brain tissue. Endogenous concentrations are extremely low, and the precise physiological role of naturally occurring DSIP remains an active area of scientific investigation.
- How can researchers determine whether DSIP is producing biological activity? In experimental studies, investigators typically evaluate objective laboratory endpoints rather than subjective observations. Depending on the research model, these may include changes in electroencephalography (EEG), circadian rhythm measurements, stress hormone biomarkers, HPA axis signaling, neurotransmitter activity, gene expression, receptor signaling, or other molecular and cellular markers relevant to the study design.
- Does DSIP bind to a specific receptor? No primary receptor has been conclusively identified. Unlike many peptide signaling molecules, DSIP has not been shown to consistently bind a single well-characterized receptor. Current evidence suggests its biological activity may result from indirect modulation of multiple signaling systems rather than activation of one specific receptor.
- Why is DSIP considered difficult to study? DSIP has a complex pharmacological profile and an incompletely understood mechanism of action. Published findings have varied between experimental models, and no definitive receptor has been identified. These factors have made it challenging to establish a single unifying mechanism for its biological activity.
- What makes DSIP different from other neuropeptides? Many neuropeptides produce their biological effects through well-defined receptors. In contrast, DSIP appears to influence several interconnected molecular signaling pathways without a clearly identified primary receptor. This has made it a unique subject within peptide and neurobiology research.
- Is additional research on DSIP needed? Yes. Although DSIP has been investigated for more than four decades, many aspects of its biology remain incompletely understood. Additional research is needed to identify its primary molecular targets, clarify its receptor interactions, and better characterize its role in cellular signaling, neuroendocrine regulation, and circadian biology.
Research Use Only: DSIP is intended exclusively for laboratory research and analytical purposes. It is an investigational research compound and has not been approved by the U.S. Food and Drug Administration (FDA).
Research Use Only
This information is provided for educational and scientific research purposes only. Products offered by Flatirons Research Co are intended strictly for laboratory and research use and are not intended for human or veterinary use, consumption, diagnosis, treatment, or prevention of disease. Nothing on this page constitutes medical advice, dosing guidance, or a recommendation for clinical use.
